Anders L.
- Country
- Sweden
- Department
- N/A
Research Overview
- Phase 3 Randomized Double-Blind Placebo-Controlled Trial Evaluating Rimegepant Efficacy and Safety in Acute Migraine Treatment in Pediatric Patients Aged 6-17 Years
- Long-term Evaluation of NMRA-335140 for Safety and Efficacy in Major Depressive Disorder Patients
- Evaluation of NMRA-335140 Efficacy in Major Depressive Disorder: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 307 of 1048 partner sites.
Specializations
Respiratory Medicine
This investigator specializes in treating chronic obstructive pulmonary disease (COPD), with particular focus on managing severe exacerbations and exploring innovative therapeutic approaches.
- Moderate to severe COPD management
- COPD exacerbation prevention
- Novel respiratory therapeutics
Mental Health
The investigator demonstrates significant expertise in major depressive disorder (MDD) treatment, including cases with concurrent symptoms like anhedonia and insomnia.
- Treatment-resistant depression
- Depression with anhedonia
- Adjunctive therapy approaches
Specialized Conditions
Additional areas of clinical interest include plaque psoriasis, allergic rhinoconjunctivitis, and migraine management in various patient populations.
- Dermatological conditions
- Allergic disorders
- Neurological conditions
Preventive Medicine
The investigator conducts research in preventive medicine, including Lyme disease vaccination and management of Type 2 diabetes mellitus with cardiovascular risk factors.
- Vaccine development
- Metabolic disorders
- Cardiovascular risk management
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.